

SAMPLE CODING

RET Fusion-positive Metastatic Non-small Cell Lung Cancer (mNSCLC)

| TYPE | CODE | | DESCRIPTION | |
|----------------------|--|---------------|--|--------------------------------------|
| Diagnosis: ICD-10-CM | C34.00 | | Malignant neoplasm of unspecified main bronchus | |
| | C34.01 | | Malignant neoplasm of right main bronchus | |
| | C34.02 | | Malignant neoplasm of left main bronchus | |
| | C34.10 | | Malignant neoplasm of upper lobe, unspecified bronchus or lung | |
| | C34.11 | | Malignant neoplasm of upper lobe, right bronchus or lung | |
| | C34.12 | | Malignant neoplasm of upper lobe, left bronchus or lung | |
| | C34.2 | | Malignant neoplasm of middle lobe, bronchus or lung | |
| | C34.30 | | Malignant neoplasm of lower lobe, unspecified bronchus or lung | |
| | C34.31 | | Malignant neoplasm of lower lobe, right bronchus or lung | |
| | C34.32 | | Malignant neoplasm of lower lobe, left bronchus or lung | |
| | C34.80 | | Malignant neoplasm of overlapping sites of unspecified bronchus and lung | |
| | C34.81 | | Malignant neoplasm of overlapping sites of right bronchus and lung | |
| | C34.82 | | Malignant neoplasm of overlapping sites of left bronchus and lung | |
| | C34.90 | | Malignant neoplasm of unspecified part of unspecified bronchus and lung | |
| | C34.91 | | Malignant neoplasm of unspecified part of right bronchus and lung | |
| | C34.92 | | Malignant neoplasm of unspecified part of left bronchus and lung | |
| | Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. | 10-digit | 11-digit | |
| | | 50242-210-60 | 50242-0210-60 | GAVRETO 100-mg capsule, bottle of 60 |
| 50242-210-90 | | 50242-0210-90 | GAVRETO 100-mg capsule, bottle of 90 | |

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

GAVRETO® is discovered by Blueprint Medicines and co-commercialized by Genentech with Blueprint Medicines Corporation in the US. Blueprint Medicines and GAVRETO are trademarks of Blueprint Medicines Corporation. The Access Solutions logo is a registered trademark of Genentech, Inc.

Please see Important Safety Information in full [Prescribing Information](#).

for **GAVRETO**[®]
 (pralsetinib)

SAMPLE CODING

RET-positive Thyroid Cancers (medullary and advanced)

| TYPE | CODE | | DESCRIPTION |
|--|--------------|---------------|---|
| Diagnosis: ICD-10-CM | C73 | | Malignant neoplasm of thyroid gland |
| | D09.3 | | Carcinoma in situ of thyroid and other endocrine glands |
| | D44.0 | | Neoplasm of uncertain behavior of thyroid gland |
| Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. | 10-digit | 11-digit | |
| | 50242-210-60 | 50242-0210-60 | GAVRETO 100-mg capsule, bottle of 60 |
| | 50242-210-90 | 50242-0210-90 | GAVRETO 100-mg capsule, bottle of 90 |

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

GAVRETO[®] is discovered by Blueprint Medicines and co-commercialized by Genentech with Blueprint Medicines Corporation in the US. Blueprint Medicines and GAVRETO are trademarks of Blueprint Medicines Corporation. The Access Solutions logo is a registered trademark of Genentech, Inc.

Please see Important Safety Information in full [Prescribing Information](#).

SAMPLE CODING

Diagnostic Testing

NGS and FISH codes refer only to identification of RET-altered advanced thyroid cancers.

| TYPE | CODE | DESCRIPTION |
|-----------|-------|--|
| CPT: PLA | 0022U | Oncomine™ Dx Target Test Thermo Fisher Scientific: Targeted genomic sequence analysis panel of 23 genes including rearrangements; FDA-approved companion diagnostic for RET fusion-positive metastatic non-small cell lung cancer |
| CPT: NGS | 81445 | 5-50 genes: Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (e.g., ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed |
| | 81455 | >50 genes: Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (e.g., ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed |
| CPT: FISH | 88364 | Each additional single probe stain procedure |
| | 88365 | Initial single probe stain procedure |
| | 88367 | Automated, computer-assisted technology, per specimen; initial single probe stain procedure |
| | 88368 | Manual, per specimen, initial single probe stain procedure |

CPT=Current Procedural Terminology; FISH=fluorescence in situ hybridization; NGS=next-generation sequencing; PLA=Proprietary Laboratory Analysis.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

GAVRETO® is discovered by Blueprint Medicines and co-commercialized by Genentech with Blueprint Medicines Corporation in the US.

Blueprint Medicines and GAVRETO are trademarks of Blueprint Medicines Corporation.

The Access Solutions logo is a registered trademark of Genentech, Inc.

Please see Important Safety Information in full [Prescribing Information](#).